As we talk to patients and physicians, there's other areas and points of differentiation that even amongst the current program. So we're already less frequent in terms of dosing administration as we talk to these patients about impact on their life in terms of travel, transit costs, having weekly IV infusions versus whether it's biweekly. And as we saw in our data from Part A, 25-day half-life means the potential for monthly or less frequent treatment. That in and of itself, as we talk to families, is a huge advantage. So we see that in the profile of the stability of our drug. We have a profile in terms of safety too, and at least in the early pieces that tells us that we shouldn't look differently than the existing standard of care. So we can provide these patients an opportunity to switch with less frequent administration and substantially more protein, which is what we're powered to see, and the ability to get the satellite cells and the fact that we see higher levels.

Nov 9, 2023 / receipt, needs a key / Paul, CEO | earnings call 2023-11-09 | transcript 48eb81a5-8584-4460-b2eb-3a71046f171a | chars 36412-37399 | segment 37